questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Lipoprotéines
Apolipoprotéines
Apolipoprotéines : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Apolipoprotéines
Tests de laboratoire
Apolipoprotéines
Analyse sanguine
Maladies cardiovasculaires
Apolipoprotéines
Imagerie médicale
Apolipoprotéines
Athérosclérose
Apolipoprotéines
Symptômes
5
Douleur thoracique
Apolipoprotéines
Métabolisme lipidique
Apolipoprotéines
Cholestérol
Apolipoprotéines
Accident vasculaire cérébral
Apolipoprotéines
Prévention
5
Prévention
Apolipoprotéines
Tabagisme
Apolipoprotéines
Contrôle de santé
Apolipoprotéines
Hydratation
Apolipoprotéines
Traitements
5
Statines
Apolipoprotéines
Médicaments hypolipémiants
Apolipoprotéines
Régime alimentaire
Apolipoprotéines
Exercice physique
Apolipoprotéines
Médecine complémentaire
Apolipoprotéines
Complications
5
Maladies cardiovasculaires
Apolipoprotéines
Maladies hépatiques
Apolipoprotéines
Santé rénale
Apolipoprotéines
Inflammation
Apolipoprotéines
Facteurs de risque
5
Hérédité
Apolipoprotéines
Vieillissement
Apolipoprotéines
Mode de vie sédentaire
Apolipoprotéines
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines : Questions médicales les plus fréquentes",
"headline": "Apolipoprotéines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Apolipoprotéines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-26",
"dateModified": "2025-02-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Lipoprotéines",
"url": "https://questionsmedicales.fr/mesh/D008074",
"about": {
"@type": "MedicalCondition",
"name": "Lipoprotéines",
"code": {
"@type": "MedicalCode",
"code": "D008074",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines M",
"alternateName": "Apolipoproteins M",
"url": "https://questionsmedicales.fr/mesh/D000075243",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines M",
"code": {
"@type": "MedicalCode",
"code": "D000075243",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines A",
"alternateName": "Apolipoproteins A",
"url": "https://questionsmedicales.fr/mesh/D001054",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines A",
"code": {
"@type": "MedicalCode",
"code": "D001054",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.200"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine A-I",
"alternateName": "Apolipoprotein A-I",
"url": "https://questionsmedicales.fr/mesh/D016632",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine A-I",
"code": {
"@type": "MedicalCode",
"code": "D016632",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.200.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine A-II",
"alternateName": "Apolipoprotein A-II",
"url": "https://questionsmedicales.fr/mesh/D016633",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine A-II",
"code": {
"@type": "MedicalCode",
"code": "D016633",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.200.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine A-V",
"alternateName": "Apolipoprotein A-V",
"url": "https://questionsmedicales.fr/mesh/D000072040",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine A-V",
"code": {
"@type": "MedicalCode",
"code": "D000072040",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.200.575"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines B",
"alternateName": "Apolipoproteins B",
"url": "https://questionsmedicales.fr/mesh/D001055",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines B",
"code": {
"@type": "MedicalCode",
"code": "D001055",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.300"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine B-48",
"alternateName": "Apolipoprotein B-48",
"url": "https://questionsmedicales.fr/mesh/D053283",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine B-48",
"code": {
"@type": "MedicalCode",
"code": "D053283",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.300.240"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine B-100",
"alternateName": "Apolipoprotein B-100",
"url": "https://questionsmedicales.fr/mesh/D053299",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine B-100",
"code": {
"@type": "MedicalCode",
"code": "D053299",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.300.249"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines C",
"alternateName": "Apolipoproteins C",
"url": "https://questionsmedicales.fr/mesh/D001056",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines C",
"code": {
"@type": "MedicalCode",
"code": "D001056",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.400"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine C-I",
"alternateName": "Apolipoprotein C-I",
"url": "https://questionsmedicales.fr/mesh/D053302",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine C-I",
"code": {
"@type": "MedicalCode",
"code": "D053302",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.400.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine C-II",
"alternateName": "Apolipoprotein C-II",
"url": "https://questionsmedicales.fr/mesh/D053304",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine C-II",
"code": {
"@type": "MedicalCode",
"code": "D053304",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.400.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine C-III",
"alternateName": "Apolipoprotein C-III",
"url": "https://questionsmedicales.fr/mesh/D053305",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine C-III",
"code": {
"@type": "MedicalCode",
"code": "D053305",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.400.875"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines D",
"alternateName": "Apolipoproteins D",
"url": "https://questionsmedicales.fr/mesh/D053399",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines D",
"code": {
"@type": "MedicalCode",
"code": "D053399",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines E",
"alternateName": "Apolipoproteins E",
"url": "https://questionsmedicales.fr/mesh/D001057",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines E",
"code": {
"@type": "MedicalCode",
"code": "D001057",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine E2",
"alternateName": "Apolipoprotein E2",
"url": "https://questionsmedicales.fr/mesh/D053329",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine E2",
"code": {
"@type": "MedicalCode",
"code": "D053329",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.500.249"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine E3",
"alternateName": "Apolipoprotein E3",
"url": "https://questionsmedicales.fr/mesh/D053318",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine E3",
"code": {
"@type": "MedicalCode",
"code": "D053318",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.500.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine E4",
"alternateName": "Apolipoprotein E4",
"url": "https://questionsmedicales.fr/mesh/D053327",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine E4",
"code": {
"@type": "MedicalCode",
"code": "D053327",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.500.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines L",
"alternateName": "Apolipoproteins L",
"url": "https://questionsmedicales.fr/mesh/D000075943",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines L",
"code": {
"@type": "MedicalCode",
"code": "D000075943",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.750"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine L1",
"alternateName": "Apolipoprotein L1",
"url": "https://questionsmedicales.fr/mesh/D000075944",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine L1",
"code": {
"@type": "MedicalCode",
"code": "D000075944",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.750.500"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines",
"alternateName": "Apolipoproteins",
"code": {
"@type": "MedicalCode",
"code": "D001053",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Joan Carles Escolà-Gil",
"url": "https://questionsmedicales.fr/author/Joan%20Carles%20Escol%C3%A0-Gil",
"affiliation": {
"@type": "Organization",
"name": "Institut de Recerca Sant Pau, 08041 Barcelona, Spain."
}
},
{
"@type": "Person",
"name": "Robert A Hegele",
"url": "https://questionsmedicales.fr/author/Robert%20A%20Hegele",
"affiliation": {
"@type": "Organization",
"name": "Robarts Research Institute, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Department of Biochemistry, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Department of Medicine, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Catherine Mounier",
"url": "https://questionsmedicales.fr/author/Catherine%20Mounier",
"affiliation": {
"@type": "Organization",
"name": "Laboratoire du Métabolisme Moléculaire des Lipides, Université du Québec à Montréal, Département des Sciences Biologiques, Case Postale 8888, Succursale Centre-ville, Montréal, QC H3C 3P8, Canada."
}
},
{
"@type": "Person",
"name": "Allan Sniderman",
"url": "https://questionsmedicales.fr/author/Allan%20Sniderman",
"affiliation": {
"@type": "Organization",
"name": "Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system.",
"datePublished": "2023-04-03",
"url": "https://questionsmedicales.fr/article/37019248",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.neubiorev.2023.105155"
}
},
{
"@type": "ScholarlyArticle",
"name": "Real-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitor Use.",
"datePublished": "2023-05-01",
"url": "https://questionsmedicales.fr/article/36795508",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/FJC.0000000000001404"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessment of serum proprotein convertase subtilisin/kexin type 9 in pediatric sepsis syndrome.",
"datePublished": "2024-07-07",
"url": "https://questionsmedicales.fr/article/38972879",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-65609-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis.",
"datePublished": "2022-07-27",
"url": "https://questionsmedicales.fr/article/35508401",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/heartjnl-2021-320556"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association between proprotein convertase subtilisin/kexin type 9 and subclinical cerebrovascular disease in the community.",
"datePublished": "2023-02-16",
"url": "https://questionsmedicales.fr/article/36727585",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ene.15723"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Lipoprotéines",
"item": "https://questionsmedicales.fr/mesh/D008074"
},
{
"@type": "ListItem",
"position": 5,
"name": "Apolipoprotéines",
"item": "https://questionsmedicales.fr/mesh/D001053"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Apolipoprotéines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Apolipoprotéines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Apolipoprotéines",
"description": "Comment diagnostiquer une anomalie des apolipoprotéines ?\nQuels tests sont utilisés pour évaluer les apolipoprotéines ?\nLes apolipoprotéines sont-elles liées aux maladies cardiovasculaires ?\nPeut-on détecter des apolipoprotéines par imagerie ?\nQuels symptômes peuvent indiquer un problème d'apolipoprotéines ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Proprotein+Convertase+9#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Apolipoprotéines",
"description": "Quels symptômes sont associés à des niveaux élevés d'apolipoprotéines ?\nLes apolipoprotéines affectent-elles le métabolisme ?\nComment les apolipoprotéines influencent-elles le cholestérol ?\nDes symptômes neurologiques peuvent-ils être liés aux apolipoprotéines ?\nLes apolipoprotéines sont-elles liées à l'obésité ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Proprotein+Convertase+9#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Apolipoprotéines",
"description": "Comment prévenir les anomalies d'apolipoprotéines ?\nLe tabagisme influence-t-il les apolipoprotéines ?\nLe stress a-t-il un impact sur les apolipoprotéines ?\nLes contrôles réguliers de santé sont-ils importants ?\nL'hydratation joue-t-elle un rôle dans la santé des apolipoprotéines ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Proprotein+Convertase+9#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Apolipoprotéines",
"description": "Quels traitements existent pour les anomalies d'apolipoprotéines ?\nLes médicaments peuvent-ils normaliser les apolipoprotéines ?\nLe régime alimentaire influence-t-il les apolipoprotéines ?\nLes exercices physiques affectent-ils les niveaux d'apolipoprotéines ?\nLes traitements naturels peuvent-ils aider les apolipoprotéines ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Proprotein+Convertase+9#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Apolipoprotéines",
"description": "Quelles complications peuvent survenir avec des apolipoprotéines anormales ?\nLes apolipoprotéines anormales peuvent-elles causer des diabètes ?\nLes troubles hépatiques sont-ils liés aux apolipoprotéines ?\nLes apolipoprotéines affectent-elles la santé rénale ?\nLes apolipoprotéines peuvent-elles influencer l'inflammation ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Proprotein+Convertase+9#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Apolipoprotéines",
"description": "Quels sont les principaux facteurs de risque pour les anomalies d'apolipoprotéines ?\nL'hérédité joue-t-elle un rôle dans les anomalies d'apolipoprotéines ?\nLe vieillissement influence-t-il les niveaux d'apolipoprotéines ?\nLe sexe a-t-il un impact sur les apolipoprotéines ?\nLe mode de vie sédentaire est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Proprotein+Convertase+9#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie des apolipoprotéines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux d'apolipoprotéines sont effectués."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer les apolipoprotéines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les dosages des apolipoprotéines A1 et B sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines sont-elles liées aux maladies cardiovasculaires ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux d'apolipoprotéines sont associés à un risque accru de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des apolipoprotéines par imagerie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la détection se fait principalement par des analyses sanguines, pas par imagerie."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème d'apolipoprotéines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme l'athérosclérose peuvent indiquer des anomalies d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à des niveaux élevés d'apolipoprotéines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés peuvent entraîner des douleurs thoraciques ou des crises cardiaques."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines affectent-elles le métabolisme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles jouent un rôle clé dans le métabolisme lipidique et peuvent causer des troubles."
}
},
{
"@type": "Question",
"name": "Comment les apolipoprotéines influencent-elles le cholestérol ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles transportent le cholestérol dans le sang, influençant les niveaux de cholestérol total."
}
},
{
"@type": "Question",
"name": "Des symptômes neurologiques peuvent-ils être liés aux apolipoprotéines ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies peuvent être associées à des troubles neurologiques comme l'AVC."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines sont-elles liées à l'obésité ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux peuvent être observés chez les personnes obèses."
}
},
{
"@type": "Question",
"name": "Comment prévenir les anomalies d'apolipoprotéines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain avec une alimentation équilibrée et de l'exercice régulier."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il les apolipoprotéines ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut augmenter le risque d'anomalies d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur les apolipoprotéines ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter les niveaux d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Les contrôles réguliers de santé sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des bilans de santé réguliers aident à détecter les anomalies tôt."
}
},
{
"@type": "Question",
"name": "L'hydratation joue-t-elle un rôle dans la santé des apolipoprotéines ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une bonne hydratation est essentielle pour le métabolisme lipidique."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les anomalies d'apolipoprotéines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les statines et les changements de mode de vie sont souvent recommandés."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils normaliser les apolipoprotéines ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent aider à réguler les niveaux d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Le régime alimentaire influence-t-il les apolipoprotéines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un régime riche en fibres et faible en graisses saturées peut aider."
}
},
{
"@type": "Question",
"name": "Les exercices physiques affectent-ils les niveaux d'apolipoprotéines ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer les niveaux d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Les traitements naturels peuvent-ils aider les apolipoprotéines ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes et suppléments peuvent soutenir la santé lipidique, mais consultez un médecin."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des apolipoprotéines anormales ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des maladies cardiovasculaires, des AVC et des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines anormales peuvent-elles causer des diabètes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont liées à un risque accru de diabète de type 2."
}
},
{
"@type": "Question",
"name": "Les troubles hépatiques sont-ils liés aux apolipoprotéines ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux peuvent être associés à des maladies hépatiques."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines affectent-elles la santé rénale ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies peuvent contribuer à des problèmes rénaux."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines peuvent-elles influencer l'inflammation ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés sont souvent associés à des états inflammatoires."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour les anomalies d'apolipoprotéines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'obésité, le tabagisme, une mauvaise alimentation et le manque d'exercice sont des facteurs clés."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans les anomalies d'apolipoprotéines ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies cardiovasculaires augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le vieillissement influence-t-il les niveaux d'apolipoprotéines ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut entraîner des modifications des niveaux d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Le sexe a-t-il un impact sur les apolipoprotéines ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des différences hormonales peuvent influencer les niveaux d'apolipoprotéines entre les sexes."
}
},
{
"@type": "Question",
"name": "Le mode de vie sédentaire est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire augmente le risque d'anomalies d'apolipoprotéines."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 20/02/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Institut de Recerca Sant Pau, 08041 Barcelona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain.
Publications dans "Apolipoprotéines" :
3 publications dans cette catégorie
Affiliations :
Robarts Research Institute, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Department of Biochemistry, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Department of Medicine, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada.
Publications dans "Apolipoprotéines" :
3 publications dans cette catégorie
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Laboratoire du Métabolisme Moléculaire des Lipides, Université du Québec à Montréal, Département des Sciences Biologiques, Case Postale 8888, Succursale Centre-ville, Montréal, QC H3C 3P8, Canada.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
Mental Health and Society Division, Douglas Mental Health University Institute, Montreal, QC, Canada.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Institute of Mental Health, Hebei Mental Health Centre, Hebei, China.
Department of Sleep Medicine, Hebei Psychiatric Hospital, Hebei, China.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Institute of Mental Health, Hebei Mental Health Centre, Hebei, China. yunshucoffee@sina.com.
Department of Sleep Medicine, Hebei Psychiatric Hospital, Hebei, China. yunshucoffee@sina.com.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, 16 Lin Cui Road, Beijing, 100101, China. zhangxy@psych.ac.cn.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Department of Neurology University of Kansas Medical Center, Kansas City, KS 66160, USA.
University of Kansas Alzheimer's Disease Center, Kansas City, KS 66160, USA.
Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Robarts Research Institute, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Department of Biochemistry, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Department of Physiology & Pharmacology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Robarts Research Institute, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada. Electronic address: mlk@robarts.ca.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
School of Public Health, Guangdong Medical University, Zhanjiang, 524023, China.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Public Health Foundation India, Gurugram, Haryana, India; Centre for Chronic Disease Control, New Delhi, India; London School of Hygiene & Tropical Medicine, United Kingdom. Electronic address: dprabhakaran@ccdcindia.org.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, Hebei Medical University, Shijiazhuang, People's Republic of China.
Department of Endocrinology, Hebei General Hospital, Shijiazhuang, People's Republic of China.
Publications dans "Apolipoprotéines" :
1 publication dans cette catégorie
Affiliations :
Center for Biomedical Research (CEBIOR), Faculty of Medicine, Universitas Diponegoro, Semarang 50275, Central Java, Indonesia.
Publications dans "Apolipoprotéines" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, CA 95817, USA.
Publications dans "Apolipoprotéines" :
1 publication dans cette catégorie
Affiliations :
Department of Psychology, University of Marlyand, College Park, MD 20742, USA.
MIND Institute, University of California Davis Medical Center, Sacramento, CA 95817, USA.
Publications dans "Apolipoprotéines" :
1 publication dans cette catégorie
Affiliations :
MIND Institute, University of California Davis Medical Center, Sacramento, CA 95817, USA.
Department of Psychiatry and Behavioral Sciences, School of Medicine, University of California Davis, Sacramento, CA 95817, USA.
Publications dans "Apolipoprotéines" :
1 publication dans cette catégorie
Affiliations :
Division of Biostatistics, School of Medicine, University of California Davis, Davis, CA 95616, USA.
Publications dans "Apolipoprotéines" :
The gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and its protein product have been widely studied for their role in cholesterol and lipid metabolism. PCSK9 increases the rate of...
Although the proprotein convertase subtilisin kexin-9 inhibitors (PCSK9i) were shown to significantly lower low-density lipoprotein and reduce atherosclerotic cardiovascular disease events in clinical...
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its tissues and organs. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme rel...
To determine the harms of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in people who need lipid-lowering therapy....
This systematic review included randomised controlled trials that compared PCSK9 inhibitors with placebo, standard care or active lipid-lowering comparators in people who need lipid-lowering therapy w...
We included 32 trials with 65 861 participants (with the median follow-up duration of 40 weeks, ranging from 24 to 146 weeks). The meta-analysis showed an incidence of injection-site reaction leading ...
PCSK9 inhibitors slightly increase the risk of severe injection-site reaction but not cataracts, gastrointestinal haemorrhage, neurocognitive events, new-onset diabetes or severe myalgia or muscular p...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new target for reducing low-density lipoprotein cholesterol and incident cardiovascular disease, including stroke. However, the clinical rele...
In community-dwelling Japanese men (n = 526) aged 46-82 years without a history of cardiovascular disease, the associations of serum PCSK9 levels with the prevalence of CSVD and ICAS were assessed usi...
The median (interquartile range) age at baseline and serum PCSK9 levels were 69 (63-74) years and 240 (205-291) ng/ml, respectively. After adjusting for traditional cardiovascular risk factors includi...
Higher circulating PCSK9 levels were independently associated with an ICAS prevalence but not with CSVD prevalence. The quantification of circulating PCSK9 levels may help to identify individuals at h...
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a posttranslational regulator of the LDL receptor (LDLR). Recent studies have proposed a role for PCSK9 in regulating immune responses. Using R...
Guidelines advocate for intensive lipid-lowering in patients with atherosclerotic cardiovascular disease (ASCVD). In May 2020, evolocumab, a proprotein convertase subtilisin-kexin type 9 (PCSK9) inhib...
To identify barriers to prescribing PCSK9 inhibitors in hospitalised patients with ASCVD....
A retrospective 3-month, single-site, observational analysis was conducted in consecutive patients undergoing percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. L...
Of 331 patients, 244 (73.7%) underwent PCI and 87 (26.3%) underwent CABG surgery. A lipid profile during or within 8 weeks of admission was measured for 202 (82.8%) patients undergoing PCI and 59 (67....
Prescribing of non-statin LDL-C-lowering therapies remains low in patients with ASCVD. Underprescribing of ezetimibe and suboptimal lipid testing rates are barriers to accessing subsidised PCSK9i ther...
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) levels have been suggested as novel atherosclerotic biomarker. PCSK9 plays important roles in the pathogenesis of atherosclerosis by regulating th...
This cross-sectional analysis enrolled 401 Caucasian patients with type II diabetes mellitus (T2DM). PCSK9 levels were measured by ELISA test, arterial stiffness was estimated by measuring carotid-fem...
Patients were divided in three tertiles according to increasing value of PCSK9. From the I to the III tertiles, there was a significant increase in high sensitivity C-reactive protein (hs-CRP), fibrin...
Our study demonstrates a close association between circulating PCSK9 levels and PWV in T2DM subjects without previous CV events even after adjusting for well-known CV risk factor and pharmacological m...
Proprotein convertase subtilisin/kexin-type 9 inhibitor (PCSK9i) treatment reduces cardiovascular events when taken over a long time for secondary prevention. Data on treatment adherence are scarce an...
Baseline data and prescription patterns of all 7302 patients with PCSK9i prescriptions dispensed on the account of Austrian Social Insurances between September 2015 and December 2020 were retrieved an...
Considering the high PDC and low discontinuation rates, the majority of patients adhere to PCSK9i treatment. Hence, in a system where PCSK9i treatment is made available at virtually no costs for patie...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces low density lipoprotein (LDL) uptake, leading to increased plasma levels of LDL. In addition, PCSK9 has been implicated in inflammation in...